<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="UTF-8" />
    <meta http-equiv="content-type" content="text/html;charset=UTF-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge" />
    <title>
      Clinical Trial in Major Depressive Disorder and Active Suicidal Ideation
      with Intent
    </title>
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />

    <link rel="stylesheet" href="./assets/css/bootstrap.min.css" />
    <link rel="stylesheet" href="./assets/css/main.css" />
    <link rel="stylesheet" href="./assets/css/style.css" />
    <link rel="stylesheet" href="./assets/css/themestyle.css" />
    <link rel="stylesheet"href="./assets/css/aspire.css" /> 

    <!-- live link start -->
    <!-- <link
      rel="stylesheet"
      href="./assets/css/bootstrap.min.css"
    />
    <link
      rel="stylesheet"
      href="https://www.janssenmd.com/sites/all/themes/jmd_subtheme/css/custom.css?q06z2c"
    />
    <link
      rel="stylesheet"
      href="https://www.janssenmd.com/sites/all/themes/jmd_subtheme/css/main.css?q06z2c"
    />
    <link
      rel="stylesheet"
      href="https://www.janssenmd.com/sites/all/themes/jmd_subtheme/css/style.css?q06z2c"
    />
    <link
      rel="stylesheet"
      href="https://www.janssenmd.com/sites/all/themes/jmd_subtheme/css/themestyle.css?q06z2c"
    />
    <link
      rel="stylesheet"
      href="./assets/css/aspire.css"
    /> -->
    <!-- live link end -->

    <script src="assets/js/jquery1.12.js"></script>
    <script src="assets/js/bootstrap.min.js"></script>
    <script src="assets/js/main.js"></script>
    <script type="text/javascript">
      /** * Janssen Science Community Cactus Inline Frame Bootstrap Script * * This script loads the main script that provides messaging functions between * parent window and iframe within Salesforce Community context. * * Per requirement, this script should support IE 11. */ !(function (
        window,
        document,
        undefined
      ) {
        if (window.self === window.top || window.name !== "jsc-iframe") return;
        var scriptElement = document.createElement("script");
        scriptElement.type = "text/javascript";
        scriptElement.src = window.frameElement.dataset.scriptUrl;
        document.head.appendChild(scriptElement);
      })(this, this.document);
    </script>
  </head>

  <body>
    <main class="themestyle">
      <div class="black-overlay" id="black-overlay"></div>
      <header>
        <div class="container-box">
          <h1 class="heading1">
            SPRAVATO<sup>®</sup> <br />
            Clinical Trials in Major Depressive Disorder and Active Suicidal
            Ideation with Intent
          </h1>
        </div>
      </header>
      <div class="container-fluid p-0">
        <div class="mobile-menu hidden-desktop" id="mobile-menu">
          <p class="mobile-header" id="mobile-header"></p>
          <div class="navbar-header">
            <button
              type="button"
              class="navbar-toggle collapsed"
              id="navbar-toggle"
              data-toggle="collapse"
              data-target="#bs-example-navbar-collapse-1"
              aria-expanded="true"
            >
              Menu <span class="icon-bar"></span> <span class="icon-bar"></span>
            </button>
          </div>
          <div
            class="navbar-collapse collapse"
            id="bs-example-navbar-collapse-1"
          >
            <nav class="navbar">
              <div id="cssmenu-1" class="container">
                <ul class="nav nav-tabs nav-mytabs myTab" role="tablist">
                  <li>
                    <a
                      data-toggle="tab"
                      class="border-width"
                      href="#executive-summary"
                      title="Executive Summary"
                      >Executive Summary</a
                    >
                  </li>

                  <li>
                    <p
                      data-toggle="collapse"
                      class="collapsed"
                      id="navbar-toggle-1"
                      data-target="#bs-example-navbar-collapse-2"
                      aria-expanded="true"
                    >
                      ASPIRE-1 and ASPIRE-2
                    </p>
                    <div
                      class="navbar-collapse-inner collapse"
                      id="bs-example-navbar-collapse-2"
                    >
                      <ul class="nav nav-tabs myTab second-tier" role="tablist">
                        <li>
                          <a
                            data-toggle="tab"
                            href="#overview"
                            title="Overview"
                            class="tab-padding"
                            >Overview</a
                          >
                        </li>
                        <li>
                          <p
                            data-toggle="collapse"
                            class="collapsed"
                            data-target="#bs-example-navbar-collapse-4"
                            aria-expanded="true"
                            id="navbar-toggle-2"
                          >
                            Study Design and Endpoints
                          </p>
                          <div
                            class="navbar-collapse-inner collapse"
                            id="bs-example-navbar-collapse-4"
                          >
                            <ul
                              class="nav nav-tabs myTab third-tier"
                              role="tablist"
                            >
                              <li>
                                <a
                                  data-toggle="tab"
                                  href="#Study-design"
                                  title="Study Design"
                                  >Study Design</a
                                >
                              </li>
                              <li>
                                <a
                                  data-toggle="tab"
                                  href="#Key-Eligibility-Criteria"
                                  title="Key Eligibility Criteria"
                                  >Key Eligibility Criteria</a
                                >
                              </li>
                              <li>
                                <a
                                  data-toggle="tab"
                                  href="#Endpoints"
                                  title="Endpoints"
                                  >Endpoints</a
                                >
                              </li>
                            </ul>
                          </div>
                        </li>
                        <li>
                          <a
                            data-toggle="tab"
                            href="#baseline-characteristics"
                            title="Baseline Characteristics"
                            >Baseline Characteristics</a
                          >
                        </li>
                        <li>
                          <p
                            data-toggle="collapse"
                            class="collapsed"
                            data-target="#bs-example-navbar-collapse-3"
                            aria-expanded="true"
                            id="navbar-toggle-3"
                          >
                            Efficacy Results
                          </p>
                          <div
                            class="navbar-collapse-inner collapse"
                            id="bs-example-navbar-collapse-3"
                          >
                            <ul
                              class="nav nav-tabs myTab third-tier"
                              role="tablist"
                            >
                              <li>
                                <a
                                  data-toggle="tab"
                                  href="#Primary-Aspire-1"
                                  title="Primary: ASPIRE-I"
                                  >Primary: ASPIRE-I</a
                                >
                              </li>
                              <li>
                                <a
                                  data-toggle="tab"
                                  href="#Primary-Aspire-2"
                                  title="Primary: ASPIRE-II"
                                  >Primary: ASPIRE-II</a
                                >
                              </li>
                              <li>
                                <a
                                  data-toggle="tab"
                                  href="#Primary-Pooled-Analysis"
                                  title="Primary: Pooled Analysis"
                                  >Primary: Pooled Analysis</a
                                >
                              </li>
                              <li>
                                <a
                                  data-toggle="tab"
                                  href="#Key-Secondary"
                                  title="Key Secondary"
                                  >Key Secondary</a
                                >
                              </li>
                              <li>
                                <a
                                  data-toggle="tab"
                                  href="#Other-Secondary"
                                  title="Other Secondary"
                                  >Other Secondary</a
                                >
                              </li>
                            </ul>
                          </div>
                        </li>
                        <li>
                          <p
                            data-toggle="collapse"
                            class="collapsed"
                            data-target="#bs-example-navbar-collapse-6"
                            aria-expanded="true"
                            id="navbar-toggle-5"
                          >
                            Safety Results
                          </p>
                          <div
                            class="navbar-collapse-inner collapse"
                            id="bs-example-navbar-collapse-6"
                          >
                            <ul
                              class="nav nav-tabs myTab third-tier"
                              role="tablist"
                            >
                              <li>
                                <a
                                  data-toggle="tab"
                                  href="#Adverse-Events"
                                  title="Adverse Events"
                                  >Adverse Events</a
                                >
                              </li>
                              <li>
                                <a
                                  data-toggle="tab"
                                  href="#Other-Safety-ASPIRE-I"
                                  title="Other Safety: ASPIRE-I"
                                  >Other Safety: ASPIRE-I</a
                                >
                              </li>
                            </ul>
                          </div>
                        </li>
                      </ul>
                    </div>
                  </li>

                  <li>
                    <p
                      data-toggle="collapse"
                      class="collapsed"
                      data-target="#bs-example-navbar-collapse-5"
                      aria-expanded="true"
                      id="navbar-toggle-4"
                    >
                      Abbreviations and References
                    </p>
                    <div
                      class="navbar-collapse-inner collapse"
                      id="bs-example-navbar-collapse-5"
                      aria-expanded="false"
                    >
                      <ul class="nav nav-tabs myTab second-tier" role="tablist">
                        <li>
                          <a
                            data-toggle="tab"
                            href="#Abbreviations"
                            title="Abbreviations"
                            >Abbreviations</a
                          >
                        </li>
                        <li>
                          <a
                            data-toggle="tab"
                            href="#Literature-Search"
                            title="Literature Search"
                            >Literature Search</a
                          >
                        </li>
                        <li>
                          <a
                            data-toggle="tab"
                            href="#References"
                            title="References"
                            >References</a
                          >
                        </li>
                      </ul>
                    </div>
                  </li>
                </ul>
              </div>
            </nav>
          </div>
        </div>
      </div>
      <div class="container-fluid">
        <div class="row">
          <!-- <div class="collapse navbar-collapse" id="bs-example-navbar-collapse-1"> -->
          <nav class="navbar hidden-mobile">
            <div id="cssmenu" class="container">
              <ul
                class="nav nav-tabs nav-mytabs myTab"
                id="myTab"
                role="tablist"
              >
                <li>
                  <a
                    data-toggle="tab"
                    class="border-width"
                    href="#executive-summary"
                    title="Executive Summary"
                    >Executive Summary</a
                  >
                </li>
                <li>
                  <a
                    data-toggle="tab"
                    href="#aspire-1-and-aspire-2"
                    title="ASPIRE-I and ASPIRE-II"
                    >ASPIRE-I and ASPIRE-II</a
                  >
                </li>

                <li>
                  <a
                    data-toggle="tab"
                    href="#abbreviation-references"
                    title="Abbreviations and References"
                    >Abbreviations and References</a
                  >
                </li>
              </ul>
            </div>
          </nav>
          <!-- </div> -->
        </div>
      </div>
      <div id="content">
        <div class="container-box">
          <div class="tab-content mytab-content" id="myTabContent">
            <div
              id="executive-summary"
              class="tab-pane fade in mb-20 text-center"
            >
              <div class="row">
                <div class="col-md-12">
                  <div class="executive-summary-block">
                    <h4 class="executive-summary-block-header">
                      <strong>Background</strong>
                    </h4>
                    <div class="executive-summary-listing">
                      <ul class="blue-bullets">
                        <li>
                          SPRAVATO has been evaluated in two subpopulations of
                          MDD in adults in clinical trials - 1) for patients
                          with treatment-resistant depression and 2) for the
                          rapid reduction of depressive symptoms in patients
                          (&lt;65 years of age) with MDD and active suicidal
                          ideation and intent. SPRAVATO was granted a
                          breakthrough therapy designation from the FDA in
                          August 2016 for this clinical program.
                        </li>
                        <li>
                          <strong
                            >SPRAVATO nasal spray has not been proven to be
                            effective in preventing suicide or in reducing
                            suicidal ideation or behavior.</strong
                          >
                        </li>
                        <li>
                          For information on ongoing clinical trials for
                          SPRAVATO nasal spray, please access the following link
                          on www.clinicaltrials.gov: <br class="line-break" /><a
                            href="https://clinicaltrials.gov/ct2/results?term=esketamine&amp;recr=Open"
                            target="_blank"
                            class="text-underline"
                            >http://jan4.me/17RroVK</a
                          >.
                        </li>
                      </ul>
                    </div>
                  </div>
                </div>
                <div class="col-md-12">
                  <div class="executive-summary-block">
                    <h4 class="executive-summary-block-header">
                      <strong
                        >Phase 3 Studies in Adults: ASPIRE-I and
                        ASPIRE-II</strong
                      >
                    </h4>
                    <div class="executive-summary-listing">
                      <ul class="blue-bullets">
                        <li>
                          Two double-blind, randomized, PBO-controlled studies
                          (ASPIRE-I [<span class="modal-title"
                            ><a
                              href="https://clinicaltrials.gov/ct2/show/NCT03039192"
                              target="_blank"
                              ><u>NCT03039192</u></a
                            ></span
                          >] and ASPIRE-II [<span class="modal-title"
                            ><a
                              style="word-break: break-all"
                              href="https://clinicaltrials.gov/ct2/show/NCT03097133"
                              target="_blank"
                              ><u>NCT03097133</u></a
                            ></span
                          >]) evaluated the efficacy and safety of SPRAVATO in
                          addition to comprehensive SOC for the rapid reduction
                          of depressive symptoms in those who have MDD and
                          active suicidal ideation with intent.<sup>1-4</sup>

                          <ul class="ml-20">
                            <li class="mt-10">
                              Primary endpoint: Both studies found that
                              SPRAVATO+SOC statistically significantly improved
                              depressive symptoms based on the MADRS total score
                              at 24 hours post first dose compared with PBO+SOC
                              (ASPIRE-I study: LSMD, -3.8; ASPIRE-II study:
                              LSMD, -3.9; <i>P </i>= 0.006 in both studies).
                            </li>
                            <li>
                              A pooled analysis of the two studies showed a LS
                              mean change in MADRS total score of -16 vs -12.1
                              (LSMD: -3.8; 95% CI: -5.75, -1.89) for the
                              SPRAVATO+SOC vs PBO+SOC groups.<sup>5</sup>
                            </li>
                            <li>
                              The most common TEAEs (≥20% in any arm) were
                              dizziness, dissociation, and nausea in ASPIRE-I
                              and dizziness, dissociation, nausea, dysgeusia,
                              somnolence, headache, and paresthesia in
                              ASPIRE-II.
                            </li>
                          </ul>
                        </li>
                        <li>
                          A post hoc analysis of North American patients (n=122)
                          in ASPIRE-I and ASPIRE-II revealed that, at baseline,
                          these patients tended to be younger, had a longer
                          duration of the current episode, a greater number of
                          depressive episodes, and reported more frequent and
                          severe suicidal thoughts than patients enrolled in the
                          trials in the rest of the world (n=328).<sup>6</sup>
                          <ul class="ml-20">
                            <li class="mt-10">
                              Patients in the SPRAVATO+SOC arm showed a
                              statistically significant improvement in the MADRS
                              total score at 24 hours post first dose compared
                              with patients in the PBO+SOC arm (-21.3 vs -14.8;
                              LSMD: -6.6; 95% CI: -10.6, -2.7). TEAEs were
                              consistent with the overall clinical trials.
                            </li>
                          </ul>
                        </li>
                      </ul>
                    </div>
                  </div>
                </div>
                <div class="col-md-12">
                  <div class="executive-summary-block">
                    <h4 class="executive-summary-block-header">
                      <strong>Phase 2 Study in Adolescents</strong>
                    </h4>
                    <div class="executive-summary-listing">
                      <ul class="blue-bullets">
                        <li>
                          A double-blind, randomized, double-dummy, psychoactive
                          PBO-controlled study is currently ongoing in
                          adolescents to assess the efficacy of SPRAVATO versus
                          oral midazolam in rapidly reducing depressive symptoms
                          in adolescents with MDD who have active suicidal
                          ideation with intent<br class="line-break" />
                          (<span class="modal-title"
                            ><a
                              href="https://clinicaltrials.gov/ct2/show/NCT03185819"
                              target="_blank"
                              ><u>NCT03185819</u></a
                            ></span
                          >).<sup>7,8</sup>
                        </li>
                      </ul>
                    </div>
                  </div>
                </div>
              </div>
            </div>
            <div id="aspire-1-and-aspire-2" class="tab-pane fade">
              <div class="hidden-mobile">
                <ul class="nav nav-tabs myTab" role="tablist">
                  <li>
                    <a
                      data-toggle="tab"
                      href="#overview"
                      title="Overview"
                      class="tab-padding"
                      >Overview</a
                    >
                  </li>
                  <li>
                    <a
                      data-toggle="tab"
                      href="#study-design-endpoint"
                      title="Study Design and Endpoints"
                      >Study Design and Endpoints</a
                    >
                  </li>
                  <li>
                    <a
                      data-toggle="tab"
                      href="#baseline-characteristics"
                      title="Baseline Characteristics"
                      >Baseline Characteristics</a
                    >
                  </li>
                  <li>
                    <a
                      data-toggle="tab"
                      href="#efficacy-results"
                      title="Efficacy Results"
                      class="tab-padding-2"
                      >Efficacy Results</a
                    >
                  </li>
                  <li>
                    <a
                      data-toggle="tab"
                      href="#safety-results"
                      title="Safety Results"
                      class="tab-padding-2"
                      >Safety Results</a
                    >
                  </li>
                </ul>
              </div>
              <div class="tab-content pb-0">
                <div id="overview" class="tab-pane fade in">
                  <div class="row">
                    <div class="col-lg-12 hidden-md hidden-sm hidden-xs">
                      <div class="row step-container">
                        <div class="col-lg-4">
                          <div class="step1 text-center">
                            <div class="boxone">
                              <h4 class="boxonemain">ASPIRE-I and ASPIRE-II</h4>
                              <div class="boxoneinner">
                                <div class="boxoneinnercircle"></div>
                                <h4 class="boxoneinnermain">
                                  Identically Designed,<br />
                                  Phase 3, Randomized,<br />
                                  Double-blind,<br />
                                  Placebo-controlled Studies
                                </h4>
                                <h4 class="boxoneinnermainone">
                                  Rapid reduction of depressive symptoms in
                                  adults with MDD with active suicidal ideation
                                  and intent
                                </h4>
                              </div>
                            </div>
                          </div>
                        </div>
                        <div class="col-lg-4">
                          <div class="step2 text-center">
                            <div class="boxtwo">
                              <h4 class="boxtwoheader">Inclusion Criteria</h4>
                              <div class="boxtwosummary">
                                <ul class="blue-bullets">
                                  <li>Age 18-64 years</li>
                                  <li>DSM-5 diagnosis of MDD</li>
                                  <li>Suicidal ideation with intent</li>
                                  <li>
                                    MADRS total score of >28 on day 1, predose
                                  </li>
                                  <li>
                                    Require acute psychiatric hospitalization
                                    due to imminent risk of suicide
                                  </li>
                                </ul>
                              </div>
                            </div>
                          </div>
                          <div class="step2 text-center">
                            <div class="boxtwo">
                              <h4 class="boxtwoheader">Exclusion Criteria</h4>
                              <div class="boxtwosummary">
                                <ul class="blue-bullets">
                                  <li>
                                    Current DSM-5 diagnosis of bipolar (or
                                    related) disorder, OCD, antisocial
                                    personality disorder, or borderline
                                    personality disorder
                                  </li>
                                  <li>
                                    Current or prior DSM-5 diagnosis of a
                                    psychotic disorder or MDD with psychosis
                                  </li>
                                  <li>
                                    History of moderate or severe substance or
                                    alcohol use within 6 months before
                                    screening.
                                  </li>
                                  <li>SBP >140mm Hg or DBP >90mm Hg</li>
                                  <li>
                                    Positive urine test result(s) for
                                    phencyclidine, cocaine, or amphetamines
                                  </li>
                                </ul>
                              </div>
                            </div>
                          </div>
                        </div>
                        <div class="col-lg-4">
                          <div class="step4 text-center">
                            <div class="boxthree">
                              <h4 class="boxthreeheader">
                                Study Design<sup>1-4</sup>
                              </h4>
                              <div class="boxthreesummary">
                                <div class="boxthree-img-block">
                                  <img
                                    src="./assets/img/overview_2.svg"
                                  />
                                  <p>
                                    SOC: Hospitalization with optimized AD and
                                    psychotherapy, enhanced by twice weekly
                                    visits during the double-blind phase
                                  </p>
                                </div>
                              </div>
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>
                    <div class="col-lg-12 hidden-md hidden-sm hidden-xs">
                      <div class="row">
                        <div class="col-lg-8">
                          <div class="step3 text-center">
                            <div class="boxfour">
                              <h4 class="boxfourheader">
                                Pooled Primary Endpoint Results<sup>5</sup>
                              </h4>
                              <div class="boxfoursummary">
                                <p>
                                  Statistically significant improvement in
                                  depressive symptoms in patients treated with
                                  SPRAVATO+SOC vs those treated with PBO+SOC
                                </p>
                                <div class="boxfour-img-block">
                                  <img
                                    src="./assets/img/overview_3.svg"
                                  />
                                </div>
                              </div>
                            </div>
                          </div>
                        </div>

                        <div class="col-lg-4">
                          <div class="step5 text-center">
                            <div class="boxfive">
                              <h4 class="boxfiveheader">
                                Safety Results<sup>3,4</sup>
                              </h4>

                              <div class="boxfivesummary">
                                <p class="boxfivecontent">
                                  <span>Most common TEAEs</span> (≥20% in either
                                  arm)
                                </p>
                                <div class="boxfivesummaryblocks">
                                  <div class="boxfivesummarydiv">
                                    <p class="boxfivesummarydiv-heading">
                                      ASPIRE-I:
                                    </p>
                                    <ul class="listing">
                                      <li>Dizziness</li>
                                      <li>Dissociation</li>
                                      <li>Nausea</li>
                                    </ul>
                                  </div>
                                  <div class="boxfivesummarydiv">
                                    <p class="boxfivesummarydiv-heading">
                                      ASPIRE-II:
                                    </p>
                                    <ul class="listing">
                                      <li>Dizziness</li>
                                      <li>Dissociation</li>
                                      <li>Nausea</li>
                                      <li>Dysgeusia</li>
                                      <li>Somnolence</li>
                                      <li>Headache</li>
                                      <li>Paresthesia</li>
                                    </ul>
                                  </div>
                                </div>
                                <ul class="blue-bullets">
                                  <li>
                                    1 death in follow-up phase in Aspire-I
                                  </li>
                                </ul>
                              </div>
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>
                    <div class="col-md-12 col-sm-12 col-xs-12 hidden-lg">
                      <div class="row step-container">
                        <div class="col-md-6 col-sm-12 col-xs-12">
                          <div class="step1 text-center">
                            <div class="boxone">
                              <h4 class="boxonemain">ASPIRE-I and ASPIRE-II</h4>
                              <div class="boxoneinner">
                                <div class="boxoneinnercircle"></div>
                                <h4 class="boxoneinnermain">
                                  Identically Designed,<br />
                                  Phase 3, Randomized,<br />
                                  Double-blind,<br />
                                  Placebo-controlled Studies
                                </h4>
                                <h4 class="boxoneinnermainone">
                                  Rapid reduction of depressive symptoms in
                                  adults with MDD with active suicidal ideation
                                  and intent
                                </h4>
                              </div>
                            </div>
                          </div>
                        </div>
                        <div class="col-md-6 col-sm-12 col-xs-12">
                          <div class="step2 text-center">
                            <div class="boxtwo">
                              <h4 class="boxtwoheader">Inclusion Criteria</h4>
                              <div class="boxtwosummary">
                                <ul class="blue-bullets">
                                  <li>Age 18-64 years</li>
                                  <li>DSM-5 diagnosis of MDD</li>
                                  <li>Suicidal ideation with intent</li>
                                  <li>
                                    MADRS total score of >28 on day 1, predose
                                  </li>
                                  <li>
                                    Require acute psychiatric hospitalization
                                    due to imminent risk of suicide
                                  </li>
                                </ul>
                              </div>
                            </div>
                          </div>
                          <div class="step2 text-center">
                            <div class="boxtwo">
                              <h4 class="boxtwoheader">Exclusion Criteria</h4>
                              <div class="boxtwosummary">
                                <ul class="blue-bullets">
                                  <li>
                                    Current DSM-5 diagnosis of bipolar (or
                                    related) disorder, OCD, antisocial
                                    personality disorder, or borderline
                                    personality disorder
                                  </li>
                                  <li>
                                    Current or prior DSM-5 diagnosis of a
                                    psychotic disorder or MDD with psychosis
                                  </li>
                                  <li>
                                    History of moderate or severe substance or
                                    alcohol use within 6 months before
                                    screening.
                                  </li>
                                  <li>SBP >140mm Hg or DBP >90mm Hg</li>
                                  <li>
                                    Positive urine test result(s) for
                                    phencyclidine, cocaine, or amphetamines
                                  </li>
                                </ul>
                              </div>
                            </div>
                          </div>
                        </div>
                      </div>
                      <div class="row step-container">
                        <div class="col-md-6 col-sm-12 col-xs-12">
                          <div class="step4 text-center">
                            <div class="boxthree">
                              <h4 class="boxthreeheader">
                                Study Design<sup>1-4</sup>
                              </h4>
                              <div class="boxthreesummary">
                                <div class="boxthree-img-block">
                                  <img
                                    src="./assets/img/overview_2.svg"
                                  />
                                  <p>
                                    SOC: Hospitalization with optimized AD and
                                    psychotherapy, enhanced by twice weekly
                                    visits during the double-blind phase
                                  </p>
                                </div>
                              </div>
                            </div>
                          </div>
                        </div>
                        <div class="col-md-6 col-sm-12 col-xs-12">
                          <div class="step5 text-center">
                            <div class="boxfive">
                              <h4 class="boxfiveheader">
                                Safety Results<sup>3,4</sup>
                              </h4>

                              <div class="boxfivesummary">
                                <p class="boxfivecontent">
                                  <span>Most common TEAEs</span> (≥20% in either
                                  arm)
                                </p>
                                <div class="boxfivesummaryblocks">
                                  <div class="boxfivesummarydiv">
                                    <p class="boxfivesummarydiv-heading">
                                      ASPIRE-I:
                                    </p>
                                    <ul class="listing">
                                      <li>Dizziness</li>
                                      <li>Dissociation</li>
                                      <li>Nausea</li>
                                    </ul>
                                  </div>
                                  <div class="boxfivesummarydiv">
                                    <p class="boxfivesummarydiv-heading">
                                      ASPIRE-II:
                                    </p>
                                    <ul class="listing">
                                      <li>Dizziness</li>
                                      <li>Dissociation</li>
                                      <li>Nausea</li>
                                      <li>Dysgeusia</li>
                                      <li>Somnolence</li>
                                      <li>Headache</li>
                                      <li>Paresthesia</li>
                                    </ul>
                                  </div>
                                </div>
                                <ul class="blue-bullets">
                                  <li>
                                    1 death in follow-up phase in Aspire-I
                                  </li>
                                </ul>
                              </div>
                            </div>
                          </div>
                        </div>
                      </div>
                      <div class="row step-container">
                        <div class="col-md-12 col-sm-12 col-xs-12">
                          <div class="step3 text-center">
                            <div class="boxfour">
                              <h4 class="boxfourheader">
                                Pooled Primary Endpoint Results<sup>5</sup>
                              </h4>
                              <div class="boxfoursummary">
                                <p>
                                  Statistically significant improvement in
                                  depressive symptoms in patients treated with
                                  SPRAVATO+SOC vs those treated with PBO+SOC
                                </p>
                                <div class="boxfour-img-block">
                                  <img
                                    src="./assets/img/overview_3.svg"
                                  />
                                </div>
                              </div>
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>

                <div id="study-design-endpoint" class="tab-pane fade in">
                  <div class="hidden-mobile">
                    <ul class="nav nav-tabs myTab" role="tablist">
                      <li>
                        <a
                          data-toggle="tab"
                          href="#Study-design"
                          title="Study Design"
                          >Study Design</a
                        >
                      </li>
                      <li>
                        <a
                          data-toggle="tab"
                          href="#Key-Eligibility-Criteria"
                          title="Key Eligibility Criteria"
                          >Key Eligibility Criteria</a
                        >
                      </li>
                      <li>
                        <a data-toggle="tab" href="#Endpoints" title="Endpoints"
                          >Endpoints</a
                        >
                      </li>
                    </ul>
                  </div>
                  <div class="tab-content pb-0 paddt-0-mobile">
                    <div id="Study-design" class="tab-pane fade in mb-20">
                      <div class="row">
                        <div class="col-md-12">
                          <ul class="blue-bullets">
                            <li>
                              ASPIRE-I (<a
                                href="https://clinicaltrials.gov/ct2/show/NCT03039192"
                                target="_blank"
                                ><span class="modal-title"
                                  ><u>NCT03039192</u></span
                                ></a
                              >) and ASPIRE-II (<a
                                href="https://clinicaltrials.gov/ct2/show/NCT03097133"
                                target="_blank"
                                ><span class="modal-title"
                                  ><u>NCT03097133</u></span
                                ></a
                              >) were 2 identically designed phase 3,
                              multicenter, 1:1 randomized, double-blind,
                              PBO-controlled studies that evaluated rapidly
                              reducing depressive symptoms in adults with MDD
                              who have active suicidal ideation with intent.<sup
                                >1-4</sup
                              >
                            </li>
                          </ul>
                          <div class="d-none d-md-block text-center mt-20">
                            <div class="parent">
                              <div class="panzoom">
                                <img
                                  src="assets/img/flow-chart.svg"
                                  alt="image"
                                />
                              </div>
                            </div>
                          </div>
                          <div
                            class="overflow-x-1170 flowchart-div d-md-none mt-20"
                          >
                            <img
                              class="mb-10"
                              src="assets/img/flow-chart.svg"
                              alt="Flowchart"
                            />
                          </div>
                          <div class="mt-20">
                            <p class="m-0 footer-text">
                              <sup>a</sup>Shorter or longer hospitalizations
                              were permitted if clinically warranted per local
                              standard practice.
                            </p>
                            <p class="m-0 footer-text">
                              <sup>b</sup>A single dose reduction from 84 mg to
                              56 mg was permitted for intolerance after day 1
                              from 84 mg to 56 mg, which continued thereafter.
                            </p>
                            <p class="m-0 footer-text">
                              <sup>c</sup>Includes the initial inpatient
                              hospitalization with newly initiated or optimized
                              AD therapy and psychotherapy, enhanced by
                              twice-weekly intensive visits during the
                              double-blind phase. AD therapy consisted of
                              monotherapy or AD plus augmentation therapy (i.e.,
                              a second AD, an atypical antipsychotic, or a mood
                              stabilizer).
                            </p>
                            <p class="m-0 footer-text">
                              <sup>d</sup>Full efficacy analysis set.
                            </p>
                          </div>
                        </div>
                      </div>
                    </div>
                    <div id="Key-Eligibility-Criteria" class="tab-pane">
                      <div class="scroll-y-key">
                        <img
                          src="assets/img/scroll-band-1.gif"
                          alt="Scroll"
                          width="100%"
                        />
                      </div>
                      <div class="overflow-x-auto">
                        <table
                          class="table table-striped table-bordered table-responsive"
                          style="min-width: 600px"
                        >
                          <thead>
                            <tr>
                              <th
                                style="vertical-align: middle"
                                class="black-color bold"
                              >
                                Inclusion Criteria<sup>3,4</sup>
                              </th>
                              <th
                                style="vertical-align: middle"
                                class="black-color bold"
                              >
                                Exclusion Criteria<sup>3,4</sup>
                              </th>
                            </tr>
                          </thead>
                          <tbody>
                            <tr>
                              <td style="width: 50%" class="align-top">
                                <ul class="blue-bullets">
                                  <li class="mb-10">Age 18-64 years</li>
                                  <li class="mb-10">DSM-5 diagnosis of MDD</li>
                                  <li class="mb-10">
                                    Suicidal ideation with intent within 24
                                    hours of randomization, confirmed by a
                                    positive response when asked:
                                    <ul class="ml-10 mt-10">
                                      <li class="ml-10">
                                        “Think about suicide (killing
                                        yourself)?”
                                      </li>
                                      <li class="ml-10">
                                        “Intend to act on thoughts of killing
                                        yourself?”
                                      </li>
                                    </ul>
                                  </li>
                                  <li class="mb-10">
                                    MADRS total score of >28 on day 1, predose
                                  </li>
                                  <li>
                                    Require acute psychiatric hospitalization
                                    due to imminent risk of suicide, and
                                    admitted voluntarily
                                  </li>
                                </ul>
                              </td>
                              <td class="align-top">
                                <ul class="blue-bullets pl-20">
                                  <li class="mb-10">
                                    Current DSM-5 diagnosis of bipolar (or
                                    related) disorder, OCD, antisocial
                                    personality disorder, or borderline
                                    personality disorder
                                  </li>
                                  <li class="mb-10">
                                    Current or prior DSM-5 diagnosis of a
                                    psychotic disorder or MDD with psychosis
                                  </li>
                                  <li class="mb-10">
                                    History of moderate or severe substance or
                                    alcohol use disorder per DSM-5 criteria
                                    within 6 months before screening
                                  </li>
                                  <li class="mb-10">
                                    SBP >140 mm Hg or DBP >90 mm Hg
                                  </li>
                                  <li class="mb-10">
                                    Positive urine test result(s) for
                                    phencyclidine, cocaine, or amphetamines
                                  </li>
                                </ul>
                              </td>
                            </tr>
                          </tbody>
                        </table>
                      </div>
                    </div>
                    <div id="Endpoints" class="tab-pane mb-20">
                      <div class="row">
                        <div class="col-md-12">
                          <h2 class="heading2">
                            Primary Efficacy Endpoint<sup>3,4</sup>
                          </h2>
                          <ul class="blue-bullets">
                            <li>
                              Change from baseline in MADRS total score at 24
                              hours after first dose.
                            </li>
                          </ul>
                          <h2 class="heading2">
                            Key Secondary Efficacy Endpoint<sup>3,4</sup>
                          </h2>
                          <ul class="blue-bullets">
                            <li>
                              Change from baseline in severity of suicidality
                              (CGI-SS-r from SIBAT) score at 24 hours after
                              first dose.
                            </li>
                          </ul>
                          <h2 class="heading2">
                            Other Secondary Efficacy Endpoints<sup>3,4</sup>
                          </h2>
                          <p>
                            Measured at 4 hours and 24 hours after first dose,
                            and through day 25:
                          </p>
                          <ul class="blue-bullets">
                            <li>
                              Percentage of participants with remission of MDD
                              (MADRS total score ≤12).
                            </li>
                            <li>
                              Reduction in CGI-SR-I and changes in FoST
                              (clinician-rated and patient-reported outcomes
                              from SIBAT), and MADRS suicidal thoughts item
                              (item 10).
                            </li>
                          </ul>
                          <div class="clearfix"></div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
                <div id="baseline-characteristics" class="tab-pane">
                  <div>
                    <ul class="blue-bullets">
                      <li>
                        Baseline characteristics were comparable across
                        treatment arms.<sup>3,4</sup>
                      </li>
                    </ul>
                  </div>
                  <div class="scroll-y">
                    <img
                      src="assets/img/scroll-band-1.gif"
                      alt="Scroll"
                      width="100%"
                    />
                  </div>
                  <div class="table-scroll-y">
                    <div class="overflow-x-auto">
                      <table
                        class="table table-striped table-bordered table-responsive mb-0 fixed-scroll-table-y"
                      >
                        <thead>
                          <tr>
                            <th
                              rowspan="2"
                              class="fixed-side box-shadow"
                              style="vertical-align: middle"
                            ></th>
                            <th
                              rowspan="1"
                              colspan="2"
                              class="text-center black-color border-right-blue bold"
                            >
                              ASPIRE-I<sup>3</sup>
                            </th>
                            <th
                              rowspan="1"
                              colspan="2"
                              class="text-center black-color border-left-blue bold"
                            >
                              ASPIRE-II<sup>4</sup>
                            </th>
                          </tr>
                          <tr>
                            <th
                              class="text-center back-blue border-right-white1 bold"
                            >
                              SPRAVATO<br />+SOC<br />(n=112)
                            </th>
                            <th
                              class="text-center back-grey border-right-white bold vertical-bottom"
                            >
                              PBO+SOC<br />
                              (n=112)
                            </th>
                            <th
                              class="text-center back-blue border-left-white border-right-white1 bold"
                            >
                              SPRAVATO<br />+SOC<br />
                              (n=114)
                            </th>
                            <th
                              class="text-center back-grey bold vertical-bottom"
                            >
                              PBO+SOC<br />
                              (n=113)
                            </th>
                          </tr>
                        </thead>
                        <tbody>
                          <tr>
                            <td class="fixed-side box-shadow">
                              Age, years, mean (SD)
                            </td>
                            <td class="text-center">40.8 (13.17)</td>
                            <td class="text-center border-right-blue">
                              37.9 (12.54)
                            </td>
                            <td class="text-center border-left-blue">
                              40.2 (12.73)
                            </td>
                            <td class="text-center">41.4 (13.43)</td>
                          </tr>
                          <tr>
                            <td class="fixed-side box-shadow">Female, n (%)</td>
                            <td class="text-center">65 (58.0)</td>
                            <td class="text-center border-right-blue">
                              73 (65.2)
                            </td>
                            <td class="text-center border-left-blue">
                              69 (60.5)
                            </td>
                            <td class="text-center">67 (59.3)</td>
                          </tr>
                          <tr>
                            <td class="fixed-side box-shadow">
                              MADRS total score, mean (SD)
                            </td>
                            <td class="text-center">41.3 (5.87)<sup>a</sup></td>
                            <td class="text-center border-right-blue">
                              41.0 (6.29)
                            </td>
                            <td class="text-center border-left-blue">
                              39.5 (5.19)
                            </td>
                            <td class="text-center">39.9 (5.76)</td>
                          </tr>
                          <tr class="bg-light-gray">
                            <td class="fixed-side box-shadow">
                              CGI-SS-r,<sup>b</sup> %
                            </td>
                            <td class="border-right-transparent"></td>
                            <td class="border-right-transparent"></td>
                            <td class="border-right-transparent"></td>
                            <td></td>
                          </tr>
                          <tr class="bg-light-gray">
                            <td class="fixed-side pl-20 box-shadow">
                              Moderately suicidal, n (%)
                            </td>
                            <td class="text-center">29 (26.1)</td>
                            <td class="text-center border-right-blue">
                              28 (25.0)
                            </td>
                            <td class="text-center border-left-blue">
                              35 (30.7)
                            </td>
                            <td class="text-center">33 (29.2)</td>
                          </tr>
                          <tr class="bg-light-gray">
                            <td class="fixed-side pl-20 box-shadow">
                              Markedly suicidal, n (%)
                            </td>
                            <td class="text-center">38 (34.2)</td>
                            <td class="text-center border-right-blue">
                              42 (37.5)
                            </td>
                            <td class="text-center border-left-blue">
                              48 (42.1)
                            </td>
                            <td class="text-center">42 (37.2)</td>
                          </tr>
                          <tr class="bg-white">
                            <td class="fixed-side pl-20 box-shadow">
                              Severely suicidal, n (%)
                            </td>
                            <td class="text-center">29 (26.1)</td>
                            <td class="text-center border-right-blue">
                              27 (24.1)
                            </td>
                            <td class="text-center border-left-blue">
                              17 (14.9)
                            </td>
                            <td class="text-center">28 (24.8)</td>
                          </tr>
                          <tr class="bg-light-gray">
                            <td class="fixed-side pl-20 box-shadow">
                              Extremely suicidal, n (%)
                            </td>
                            <td class="text-center">4 (3.6)</td>
                            <td class="text-center border-right-blue">
                              1 (0.9)
                            </td>
                            <td class="text-center border-left-blue">
                              3 (2.6)
                            </td>
                            <td class="text-center">1 (0.9)</td>
                          </tr>
                          <tr class="bg-white">
                            <td class="fixed-side box-shadow">
                              Prior suicide attempts, n (%)
                            </td>
                            <td class="text-center">66 (59.5)<sup>a</sup></td>
                            <td class="text-center border-right-blue">
                              68 (60.7)
                            </td>
                            <td class="text-center border-left-blue">
                              78 (68.4)
                            </td>
                            <td class="text-center">72 (63.7)</td>
                          </tr>
                          <tr>
                            <td class="fixed-side pl-20 box-shadow">
                              Attempted suicide within the last month
                            </td>
                            <td class="text-center">32 (28.6)</td>
                            <td class="text-center border-right-blue">
                              31 (27.7)
                            </td>
                            <td class="text-center border-left-blue">
                              36 (31.6)
                            </td>
                            <td class="text-center">24 (21.2)</td>
                          </tr>
                          <tr class="bg-white">
                            <td class="fixed-side box-shadow">
                              SOC-ADs as randomized, n (%)
                            </td>
                            <td class="border-right-transparent"></td>
                            <td class="border-right-transparent"></td>
                            <td class="border-right-transparent"></td>
                            <td></td>
                          </tr>
                          <tr class="bg-light-gray">
                            <td class="fixed-side pl-20 box-shadow">
                              AD monotherapy
                            </td>
                            <td class="text-center">59 (52.7)</td>
                            <td class="text-center border-right-blue">
                              65 (58.0)
                            </td>
                            <td class="text-center border-left-blue">
                              45 (39.5)
                            </td>
                            <td class="text-center">43 (38.1)</td>
                          </tr>
                          <tr class="bg-light-gray">
                            <td class="pl-20 fixed-side box-shadow">
                              AD + augmentation therapy
                            </td>
                            <td class="text-center">53 (47.3)</td>
                            <td class="text-center border-right-blue">
                              47 (42.0)
                            </td>
                            <td class="text-center border-left-blue">
                              69 (60.5)
                            </td>
                            <td class="text-center">70 (61.9)</td>
                          </tr>
                        </tbody>
                      </table>
                    </div>
                  </div>
                  <p class="mt-20 footer-text"><sup>a</sup>n=111.</p>
                  <p class="mb-20 footer-text">
                    <sup>b</sup>Data are not shown for those who were "normal",
                    "questionably suicidal", and "mildly suicidal".
                  </p>
                </div>

                <div id="efficacy-results" class="tab-pane fade">
                  <div class="hidden-mobile">
                    <ul class="nav nav-tabs myTab" role="tablist">
                      <li>
                        <a
                          data-toggle="tab"
                          href="#Primary-Aspire-1"
                          title="Primary ASPIRE-I"
                          >Primary: ASPIRE-I</a
                        >
                      </li>
                      <li>
                        <a
                          data-toggle="tab"
                          href="#Primary-Aspire-2"
                          title="Primary ASPIRE-II"
                          >Primary: ASPIRE-II</a
                        >
                      </li>
                      <li>
                        <a
                          data-toggle="tab"
                          href="#Primary-Pooled-Analysis"
                          title="Primary:Pooled Analysis"
                          >Primary: Pooled Analysis</a
                        >
                      </li>
                      <li>
                        <a
                          data-toggle="tab"
                          href="#Key-Secondary"
                          title="Key Secondary"
                          >Key Secondary</a
                        >
                      </li>
                      <li>
                        <a
                          data-toggle="tab"
                          href="#Other-Secondary"
                          title="Other Secondary"
                          >Other Secondary</a
                        >
                      </li>
                    </ul>
                  </div>
                  <div class="tab-content pb-0 paddt-0-mobile">
                    <div id="Primary-Aspire-1" class="tab-pane fade in">
                      <ul class="blue-bullets mt-10">
                        <li>
                          Statistically significant improvement in change from
                          baseline of mean MADRS total score at 24 hours after
                          first dose was noted in SPRAVATO+SOC vs PBO+SOC.<sup
                            >3,4</sup
                          >
                          <ul class="ml-20 mt-10">
                            <li>
                              Treatment effect of SPRAVATO+SOC on depressive
                              symptoms was observed at 4 hours after the initial
                              dose and at all time points compared to PBO+SOC.
                            </li>
                          </ul>
                        </li>
                      </ul>

                      <div>
                        <h1
                          class="heading1 text-center black-color mt-20 mb-20"
                        >
                          ASPIRE-I<sup>3</sup>
                        </h1>
                        <div class="text-center p-20 text-center">
                          <img
                            src="assets/img/line-chart-1.svg"
                            alt="Chart"
                            width="900px"
                          />
                        </div>
                      </div>
                      <div class="row">
                        <div class="col-md-12 mtb-30">
                          <div class="text-center">
                            <a
                              class="btn btn-default hide-menu"
                              data-toggle="modal"
                              data-target="#ASPIREModal-5"
                              >MADRS Total Score in the Double-Blind and
                              Follow-up Phases in ASPIRE-I</a
                            >
                          </div>
                          <div class="clearfix"></div>
                        </div>
                      </div>
                    </div>

                    <div id="Primary-Aspire-2" class="tab-pane fade">
                      <div>
                        <h1
                          class="heading1 text-center black-color mt-20 mb-20"
                        >
                          ASPIRE-II<sup>4</sup>
                        </h1>
                        <div class="text-center p-20 text-center">
                          <img
                            src="assets/img/line-chart-2.svg"
                            alt="Chart"
                            width="900px"
                          />
                        </div>
                      </div>
                    </div>

                    <div id="Primary-Pooled-Analysis" class="tab-pane fade">
                      <div>
                        <h1
                          class="heading1 text-center black-color mt-20 mb-20"
                        >
                          ASPIRE-I and ASPIRE-II Pooled Analysis<sup>5</sup>
                        </h1>
                        <div class="text-center p-20 text-center">
                          <img
                            src="assets/img/line-chart-3.svg"
                            alt="Chart"
                            width="900px"
                          />
                        </div>
                      </div>
                      <div class="row">
                        <div class="col-md-12 mtb-30">
                          <div class="text-center">
                            <a
                              class="btn btn-default hide-menu"
                              data-toggle="modal"
                              data-target="#ASPIREModal-2"
                              >Subgroup Analysis of the Pooled Primary Efficacy
                              Endpoint</a
                            >
                          </div>
                          <div class="clearfix"></div>
                        </div>
                      </div>
                    </div>
                    <div id="Key-Secondary" class="tab-pane fade">
                      <h1 class="heading1 black-color mt-20 mb-20">
                        SPRAVATO nasal spray has not been studied or proven to
                        be effective in preventing suicide.
                      </h1>

                      <ul class="blue-bullets mt-10">
                        <li>
                          While improvements in the severity of suicidality
                          scores were noted in SPRAVATO+SOC and PBO+SOC arms at
                          24 hours after the first dose, the difference was not
                          statistically significant.<sup>3,4</sup>
                        </li>
                      </ul>
                      <div class="scroll-y">
                        <img
                          src="assets/img/scroll-band-1.gif"
                          alt="Scroll"
                          width="100%"
                        />
                      </div>
                      <div class="table-scroll-x">
                        <div class="overflow-x-auto">
                          <table
                            class="table table-striped table-bordered table-responsive mb-0 fixed-scroll-table-x"
                          >
                            <thead>
                              <tr>
                                <th
                                  rowspan="2"
                                  class="fixed-side box-shadow bold"
                                  style="vertical-align: middle"
                                ></th>
                                <th
                                  rowspan="1"
                                  colspan="2"
                                  class="text-center black-color border-right-blue bold"
                                >
                                  ASPIRE-I<sup>3</sup>
                                </th>
                                <th
                                  rowspan="1"
                                  colspan="2"
                                  class="text-center black-color border-left-blue bold"
                                >
                                  ASPIRE-II<sup>4</sup>
                                </th>
                              </tr>
                              <tr>
                                <th
                                  class="text-center back-blue border-right-white1 box-shadow bold"
                                >
                                  SPRAVATO<br />+SOC <br />(n=112)
                                </th>
                                <th
                                  class="text-center back-grey border-right-white bold vertical-bottom"
                                >
                                  PBO+SOC <br />(n=112)
                                </th>
                                <th
                                  class="text-center back-blue border-left-white border-right-white1 bold"
                                >
                                  SPRAVATO<br />+SOC<br />
                                  (n=114)
                                </th>
                                <th
                                  class="text-center back-grey bold vertical-bottom"
                                >
                                  PBO+SOC<br />
                                  (n=113)
                                </th>
                              </tr>
                            </thead>
                            <tbody>
                              <tr>
                                <td
                                  rowspan="2"
                                  class="fixed-side box-shadow"
                                  style="vertical-align: middle"
                                >
                                  Change from baseline in CGI-SS-r total score,
                                  median (range)
                                </td>
                                <td class="text-center">-1.0 (-6; 2)</td>
                                <td class="text-center border-right-blue">
                                  -1.0 (-5; 1)
                                </td>
                                <td class="text-center border-left-blue">
                                  -1.0 (-6; 2)
                                </td>
                                <td class="text-center">-1.0 (-5; 2)</td>
                              </tr>
                              <td
                                rowspan="1"
                                colspan="2"
                                class="text-center border-right-blue"
                              >
                                <i>P </i>= 0.107
                              </td>
                              <td
                                rowspan="1"
                                colspan="2"
                                class="text-center border-left-blue"
                              >
                                <i>P </i>= 0.379
                              </td>
                            </tbody>
                          </table>
                        </div>
                      </div>

                      <div class="row">
                        <div class="col-md-12 mtb-30">
                          <div class="text-center">
                            <a
                              class="btn btn-default hide-menu"
                              data-toggle="modal"
                              data-target="#ASPIREModal-4"
                              >Pooled Analysis of Secondary Suicidality
                              Endpoints</a
                            >
                          </div>
                          <div class="clearfix"></div>
                        </div>
                      </div>
                    </div>

                    <div id="Other-Secondary" class="tab-pane">
                      <h1 class="heading1 black-color mt-20 mb-20">
                        SPRAVATO nasal spray has not been studied or proven to
                        be effective in preventing suicide.
                      </h1>

                      <ul class="blue-bullets mt-10">
                        <li>
                          More patients achieved remission (MADRS total score of
                          ≤12) in the SPRAVATO+SOC vs PBO+SOC at all timepoints
                          during the double-blind phase.<sup>3,4</sup>
                        </li>
                      </ul>
                      <div class="text-center p-20 text-center">
                        <img
                          src="assets/img/bar-chart.svg"
                          alt="Chart"
                          width="800px"
                        />
                      </div>

                      <div class="row">
                        <div class="col-md-12 mtb-30">
                          <div class="text-center">
                            <a
                              class="btn btn-default hide-menu"
                              data-toggle="modal"
                              data-target="#ASPIREModal-3"
                              >Pooled Analysis of Remission</a
                            >
                          </div>
                          <div class="clearfix"></div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
                <div id="safety-results" class="tab-pane fade">
                  <div class="hidden-mobile">
                    <ul class="nav nav-tabs myTab" role="tablist">
                      <li>
                        <a
                          data-toggle="tab"
                          href="#Adverse-Events"
                          title="Adverse Events"
                          >Adverse Events</a
                        >
                      </li>
                      <li>
                        <a
                          data-toggle="tab"
                          href="#Other-Safety-ASPIRE-I"
                          title="Other Safety: ASPIRE-I"
                          >Other Safety: ASPIRE-I</a
                        >
                      </li>
                    </ul>
                  </div>
                  <div class="tab-content pb-0 paddt-0-mobile">
                    <div id="Adverse-Events" class="tab-pane fade">
                      <div class="scroll-y">
                        <img
                          src="assets/img/scroll-band-1.gif"
                          alt="Scroll"
                          width="100%"
                        />
                      </div>
                      <div class="table-scroll">
                        <div class="overflow-x-auto">
                          <table
                            class="table table-striped table-bordered table-responsive mb-0 fixed-scroll-table"
                          >
                            <thead>
                              <tr>
                                <th
                                  rowspan="2"
                                  class="fixed-side black-color box-shadow bold"
                                  style="vertical-align: middle !important"
                                >
                                  Adverse Event
                                </th>
                                <th
                                  rowspan="1"
                                  colspan="2"
                                  class="text-center black-color border-right-blue bold"
                                >
                                  ASPIRE-I<sup>3</sup>
                                </th>
                                <th
                                  rowspan="1"
                                  colspan="2"
                                  class="text-center black-color border-left-blue bold"
                                >
                                  ASPIRE-II<sup>4</sup>
                                </th>
                              </tr>
                              <tr>
                                <th
                                  class="text-center back-blue border-right-white1 box-shadow bold"
                                >
                                  SPRAVATO<br />+SOC<br />(n=113)
                                </th>
                                <th
                                  class="text-center back-grey border-right-white bold vertical-bottom"
                                >
                                  PBO+SOC<br />
                                  (n=112)
                                </th>
                                <th
                                  class="text-center back-blue border-left-white border-right-white1 bold"
                                >
                                  SPRAVATO<br />+SOC<br />
                                  (n=114)
                                </th>
                                <th
                                  class="text-center back-grey bold vertical-bottom"
                                >
                                  PBO+SOC<br />
                                  (n=113)
                                </th>
                              </tr>
                            </thead>
                            <tbody>
                              <tr>
                                <td class="fixed-side box-shadow">
                                  ≥1 TEAE during double-blind phase, n (%)
                                </td>
                                <td class="text-center">100 (88.5)</td>
                                <td class="text-center border-right-blue">
                                  83 (74.1)
                                </td>
                                <td class="text-center border-left-blue">
                                  104 (91.2)
                                </td>
                                <td class="text-center">87 (77.0)</td>
                              </tr>
                              <tr>
                                <td class="fixed-side box-shadow">
                                  Discontinuations of study drug due to TEAEs in
                                  the double-blind phase, n (%)
                                </td>
                                <td class="text-center">5 (4.4)</td>
                                <td class="text-center border-right-blue">
                                  5 (4.5)
                                </td>
                                <td class="text-center border-left-blue">
                                  9 (7.9)
                                </td>
                                <td class="text-center">3 (2.7)</td>
                              </tr>
                              <tr>
                                <td class="fixed-side box-shadow">
                                  Serious TEAEs in the double-blind phase, n (%)
                                </td>
                                <td class="text-center">4 (3.5)<sup>a</sup></td>
                                <td class="text-center border-right-blue">
                                  6 (5.4)<sup>b</sup>
                                </td>
                                <td class="text-center border-left-blue">
                                  5 (4.4)<sup>c</sup>
                                </td>
                                <td class="text-center">6 (5.3)<sup>d</sup></td>
                              </tr>
                              <tr class="bg-light-gray">
                                <td class="fixed-side box-shadow">
                                  Deaths in the double-blind phase, n
                                </td>
                                <td class="text-center">0</td>
                                <td class="text-center border-right-blue">0</td>
                                <td class="text-center border-left-blue">0</td>
                                <td class="text-center">0</td>
                              </tr>
                              <tr class="bg-light-gray">
                                <td class="fixed-side box-shadow">
                                  Deaths in the follow-up phase, n
                                </td>
                                <td class="text-center">1<sup>e</sup></td>
                                <td class="text-center border-right-blue">0</td>
                                <td class="text-center border-left-blue">0</td>
                                <td class="text-center">0</td>
                              </tr>
                            </tbody>
                          </table>
                        </div>
                      </div>
                      <div class="mt-20">
                        <p class="m-0 footer-text">
                          <sup>a</sup>Included suicidal depression (n=2),
                          depression, suicide attempt, and diabetic ketoacidosis
                          (n=1 each).
                        </p>
                        <p class="m-0 footer-text">
                          <sup>b</sup>Included suicidal ideation (n=2),
                          depression suicidal, depression, suicide attempt,
                          aggression, and hypertransaminasemia (n=1 each).
                        </p>
                        <p class="m-0 footer-text">
                          <sup>c</sup>Included suicide attempt (n=3), suicidal
                          ideation, and depersonalization/derealization disorder
                          (n=1 each).
                        </p>
                        <p class="m-0 footer-text">
                          <sup>d</sup>Included suicide attempt (n=3), suicidal
                          ideation (n=2), depression, arrhythmia, pericardial
                          effusion, and pneumothorax (n=1 each).
                        </p>
                        <p class="m-0 footer-text">
                          <sup>e</sup>Completed suicide 3 days after receiving
                          her last dose of SPRAVATO and was considered by
                          investigators to be unrelated to SPRAVATO. The patient
                          had a history of 5 prior suicide attempts.
                        </p>
                      </div>

                      <div class="row">
                        <div class="col-md-12 mt-30 mb-10">
                          <div class="text-center">
                            <a
                              class="btn btn-default hide-menu"
                              data-toggle="modal"
                              data-target="#myModal3"
                              >Most Common (≥10% in Either Group) TEAEs During
                              the Double-Blind Phase</a
                            >
                          </div>
                          <div class="clearfix"></div>
                        </div>
                      </div>

                      <div class="row">
                        <div class="col-md-12">
                          <div class="text-center">
                            <a
                              class="btn btn-default hide-menu"
                              data-toggle="modal"
                              data-target="#myModal6"
                              >TEAEs and SAEs During the Follow-up Phase:
                              ASPIRE-I</a
                            >
                          </div>
                          <div class="clearfix"></div>
                        </div>
                      </div>
                    </div>
                    <div id="Other-Safety-ASPIRE-I" class="tab-pane fade">
                      <ul class="blue-bullets mt-10">
                        <li>
                          <span class="bold blue">Most adverse events</span>
                          occurred during the intranasal dosing days
                          (SPRAVATO+SOC, 91.0%; PBO+SOC, 70.3%) and of these,
                          most resolved on the same day (SPRAVATO+SOC, 94.9%;
                          PBO+SOC, 85.7%).<sup>3</sup>
                        </li>
                      </ul>
                      <ul class="blue-bullets mt-10">
                        <li>
                          All depression and
                          <span class="bold blue"
                            >suicide-related adverse events</span
                          >
                          during the double-blind phase were considered
                          unrelated to SPRAVATO by the investigators.<sup
                            >3</sup
                          >
                          <ul class="ml-20">
                            <li class="mt-10">
                              All patients who attempted suicide during the
                              study had additionally attempted suicide during
                              the month before randomization.<sup>3</sup>
                            </li>
                            <li>
                              A rapid reduction in<span class="bold blue">
                                severity of suicidality</span
                              >
                              was observed in patients across both treatment
                              groups. The difference in reduction between the
                              two groups was not statistically significant and
                              this was likely due to the following:<sup>3</sup>

                              <ul class="ml-20">
                                <li class="mt-10">
                                  Acute suicidal crisis being diffused during
                                  inpatient psychiatric hospitalization.
                                </li>
                                <li>
                                  SOC being augmented by twice-weekly visits,
                                  extensive clinical contact, and concomitant
                                  use of permitted benzodiazepine.
                                </li>
                              </ul>
                            </li>
                          </ul>
                        </li>
                      </ul>
                      <ul class="blue-bullets mt-10">
                        <li>
                          The proportion of patients with<span
                            class="bold blue"
                          >
                            MOAA/S</span
                          >
                          score ≤ 3 was greater in the SPRAVATO+SOC group
                          (11.5%) than in the PBO+SOC group (0.9%). No medical
                          intervention was required for these patients.<sup
                            >3</sup
                          >
                        </li>
                      </ul>
                      <ul class="blue-bullets mt-10">
                        <li>
                          Consistent with the SPRAVATO studies in
                          treatment-resistant depression,
                          <span class="bold blue">blood pressure</span> and
                          <span class="bold blue"> dissociation</span> (as
                          assessed by the CADSS) peaked at 40 minutes postdose
                          and began to approach baseline levels at 90 minutes
                          postdose.<sup>3</sup>
                        </li>
                      </ul>
                    </div>
                  </div>
                </div>
              </div>
            </div>
            <div id="abbreviation-references" class="tab-pane fade">
              <div class="hidden-mobile">
                <ul class="nav nav-tabs myTab" role="tablist">
                  <li>
                    <a
                      data-toggle="tab"
                      href="#Abbreviations"
                      title="Abbreviations"
                      >Abbreviations</a
                    >
                  </li>
                  <li>
                    <a
                      data-toggle="tab"
                      href="#Literature-Search"
                      title="Literature Search"
                      >Literature Search</a
                    >
                  </li>
                  <li>
                    <a data-toggle="tab" href="#References" title="References"
                      >References</a
                    >
                  </li>
                </ul>
              </div>
              <div class="tab-content pb-0">
                <div id="Abbreviations" class="tab-pane fade in">
                  <div class="scroll-y-abb">
                    <img
                      src="assets/img/scroll-band-1.gif"
                      alt="Scroll"
                      width="100%"
                    />
                  </div>
                  <div class="overflow-x-auto">
                    <table
                      class="table table-bordered table-responsive table-w-s"
                    >
                      <tbody>
                        <tr>
                          <td><strong>AD</strong></td>
                          <td>Antidepressant</td>
                          <td><strong>MMRM</strong></td>
                          <td>Mixed-effects model using repeated measures</td>
                        </tr>
                        <tr>
                          <td><strong>CADSS</strong></td>
                          <td>
                            Clinician Administered Dissociative States Scale
                          </td>
                          <td><strong>MDD</strong></td>
                          <td>Major depressive disorder</td>
                        </tr>
                        <tr>
                          <td><strong>CGI-SR-I</strong></td>
                          <td>
                            Clinical Global Impression - Imminent Suicide Risk
                          </td>
                          <td><strong>MOAA/S</strong></td>
                          <td>
                            Modified Observer’s Assessment of Alertness Sedation
                          </td>
                        </tr>
                        <tr>
                          <td><strong>CGI-SS-r</strong></td>
                          <td>
                            Clinical Global Impression - Severity of Suicidality
                            - revised
                          </td>

                          <td><strong>OCD</strong></td>
                          <td>Obsessive compulsive disorder</td>
                        </tr>
                        <tr>
                          <td><strong>CI</strong></td>
                          <td>Confidence interval</td>
                          <td><strong>PBO</strong></td>
                          <td>Placebo</td>
                        </tr>
                        <tr>
                          <td><strong>DBP</strong></td>
                          <td>Diastolic blood pressure</td>
                          <td><strong>SBP</strong></td>
                          <td>Systolic blood pressure</td>
                        </tr>
                        <tr>
                          <td><strong>DSM-5</strong></td>
                          <td>
                            Diagnostic and Statistical Manual of Mental
                            Disorders (5th edition)
                          </td>
                          <td><strong>SD</strong></td>
                          <td>Standard deviation</td>
                        </tr>
                        <tr>
                          <td><strong>FDA</strong></td>
                          <td>Food and Drug Administration</td>
                          <td><strong>SE</strong></td>
                          <td>Standard error</td>
                        </tr>
                        <tr>
                          <td><strong>FoST</strong></td>
                          <td>Frequency of Suicidal Thinking</td>
                          <td><strong>SIBAT</strong></td>
                          <td>Suicide Ideation and Behavior Assessment Tool</td>
                        </tr>
                        <tr>
                          <td><strong>LS</strong></td>
                          <td>Least squares</td>
                          <td><strong>SAE</strong></td>
                          <td>Serious adverse event</td>
                        </tr>
                        <tr>
                          <td><strong>LSMD</strong></td>
                          <td>Least squares mean difference</td>
                          <td><strong>SOC</strong></td>
                          <td>Standard of care</td>
                        </tr>
                        <tr>
                          <td><strong>MADRS</strong></td>
                          <td>Montgomery-Ǻsberg Depression Rating Scale</td>
                          <td><strong>TEAE</strong></td>
                          <td>Treatment-emergent adverse event</td>
                        </tr>
                      </tbody>
                    </table>
                  </div>
                </div>
                <div id="Literature-Search" class="tab-pane fade">
                  <p>
                    A literature search of MEDLINE<sup>®</sup> and EMBASE<sup
                      >®</sup
                    >
                    (and/or other resources, including internal/external
                    databases) pertaining to this topic was conducted on 20 May
                    2020.
                  </p>
                  <p class="pb-0">
                    This response contains a summary of phase 3 studies in
                    adults with MDD and active suicidal ideation with intent and
                    an ongoing phase 2 study in adolescents. The citation for
                    the phase 2 study in adults<sup>9</sup> is located within
                    the References tab.
                  </p>
                </div>
                <div id="References" class="tab-pane fade">
                  <ol class="pl-20">
                    <li class="mb-10">
                      Janssen Research &amp; Development, LLC. A double-blind,
                      randomized, placebo-controlled study to evaluate the
                      efficacy and safety of intranasal esketamine in addition
                      to comprehensive standard of care for the rapid reduction
                      of the symptoms of major depressive disorder, including
                      suicidal ideation, in adults subjects assessed to be at
                      imminent risk for suicide. In: ClinicalTrials.gov
                      [Internet]. Bethesda (MD): National Library of Medicine
                      (US). 2000- [1/24/2018]. Available from:
                      <a
                        style="word-break: break-all"
                        href="https://clinicaltrials.gov/ct2/show/NCT03097133"
                        target="_blank"
                        class="text-underline"
                        >https://clinicaltrials.gov/ct2/show/NCT03097133</a
                      >
                      NLM Identifier: NCT03097133.
                    </li>
                    <li class="mb-10">
                      Janssen Research &amp; Development, LLC. A study of the
                      efficacy and safety of intranasal esketamine in the rapid
                      reduction of symptoms of major depressive disorders, in
                      adult at imminent risk for suicide. In: ClinicalTrials.gov
                      [Internet]. Bethesda (MD): National Library of Medicine
                      (US). 2000- [1/24/2018]. Available from:
                      <a
                        style="word-break: break-all"
                        href="https://clinicaltrials.gov/ct2/show/NCT03039192"
                        target="_blank"
                        class="text-underline"
                        >https://clinicaltrials.gov/ct2/show/NCT03039192</a
                      >
                      NLM Identifier: NCT03039192.
                    </li>
                    <li class="mb-10">
                      Fu DJ, Ionescu DF, Li X, et al. Esketamine nasal spray for
                      rapid reduction of major depressive disorder symptoms in
                      patients who have active suicidal ideation with intent:
                      double-blind randomized study (ASPIRE I).<i>
                        J Clin Psychiatry.</i
                      >
                      2020;81(3):19m13191.
                    </li>
                    <li class="mb-10">
                      Ionescu DF, Ionescu DF, Fu DJ, et al. Esketamine nasal
                      spray for rapid reduction of major depressive disorder
                      symptoms in patients at imminent risk for suicide:
                      ASPIRE-II study. Poster presented at: 32nd European
                      College of Neuropsychopharmacology (ECNP); September 7-10,
                      2019; Copenhagen, Denmark.
                    </li>
                    <li class="mb-10">
                      Canuso CM, Fu DJ, Ionescu DF, et al. Esketamine nasal
                      spray for rapid reduction of depressive symptoms in adult
                      patients with major depressive disorder at imminent risk
                      for suicide: results from the phase 3 program. Poster
                      presented at: 58th Annual meeting of American College of
                      Neuropsychopharmacology (ACNP); December 8-11, 2019;
                      Orlando, FL.
                    </li>
                    <li class="mb-10">
                      Nash AI, Turkoz I, Fu DJ, et al. Esketamine nasal spray
                      for rapid reduction of major depressive disorder symptoms
                      in adult patients at imminent risk for suicide: a post hoc
                      analysis of North American subjects. Poster presented at:
                      58th Annual meeting of American College of
                      Neuropsychopharmacology (ACNP); December 8-11, 2020;
                      Orlando, FL.
                    </li>
                    <li class="mb-10">
                      Pandina G, Kosik-Gonzalez C, Canuso CM. Esketamine nasal
                      spray for rapid reduction of major depressive disorder
                      symptoms in adolescents at imminent suicidal risk:
                      rationale, design and progress of a phase 2 study. Poster
                      presented at: The 17th European Symposium on Suicide and
                      Suicidal Behavior (ESSSB); September 5-8, 2018; Ghent,
                      Belgium.
                    </li>
                    <li class="mb-10">
                      Janssen Research &amp; Development, LLC. A double-blind,
                      randomized, psychoactive placebo-controlled, study to
                      evaluate the efficacy and safety of 3 fixed doses (28 mg,
                      56 mg and 84 mg) of intranasal esketamine in addition to
                      comprehensive standard of care for the rapid reduction of
                      the symptoms of major depressive disorder, including
                      suicidal ideation, in pediatric subjects assessed to be at
                      imminent risk for suicide. In: ClinicalTrials.gov
                      [Internet]. Besthesda (MD): National Library of Medicine
                      (US). 2000- [cited 2018 October 4]. Available from:
                      <a
                        style="word-break: break-all"
                        href="https://clinicaltrials.gov/ct2/show/NCT03185819"
                        target="_blank"
                        class="text-underline"
                        >https://clinicaltrials.gov/ct2/show/NCT03185819</a
                      >
                      NLM Identifier: NCT03185819.
                    </li>
                    <li class="mb-10">
                      Canuso C, Singh J, Fedgchin M, et al. Efficacy and safety
                      of intranasal esketamine for the rapid reduction of
                      symptoms of depression and suicidality in patients at
                      imminent risk for suicide: results of a double-blind,
                      randomized, placebo-controlled study [published online
                      ahead of print].<em> Am J Psychiatry</em> 2018.
                      doi:10.1176/appi.ajp.2018.17060720.2018.
                    </li>
                  </ol>
                </div>
              </div>
            </div>
          </div>
          <!-- <a href="assets/pdf/SPRAVATO.pdf" class="download_pdf" title="Download PDF Version" target="_blank"></a> -->

          <!-- my moodal (priyanka) -->
          <div class="modal fade" id="ASPIREModal-1" role="dialog">
            <div class="modal-dialog">
              <!-- Modal content-->
              <div class="modal-content">
                <div class="modal-header">
                  <a
                    href="#"
                    class="close glyphicon glyphicon-remove"
                    data-dismiss="modal"
                  ></a>
                  <h3 class="modal-title">Literature Search</h3>
                </div>
                <div class="modal-body">
                  <p>
                    A literature search of MEDLINE® and EMBASE® (and/or other
                    resources, including internal/external databases) pertaining
                    to this topic was conducted on 23 January 2020.
                  </p>
                  <p>
                    This response contains a summary of phase 3 studies in
                    adults with MDD and active suicidal ideation with intent and
                    an ongoing phase 2 study in adolescents. The citation for a
                    phase 2 study in adults9 is cited below.
                  </p>
                </div>
              </div>
            </div>
          </div>

          <div class="modal fade" id="ASPIREModal-2" role="dialog">
            <div class="modal-dialog">
              <!-- Modal content-->
              <div class="modal-content">
                <div class="modal-header">
                  <a
                    href="#"
                    class="close glyphicon glyphicon-remove"
                    data-dismiss="modal"
                  ></a>
                  <h3 class="modal-title">
                    Subgroup Analysis of the Pooled Primary Efficacy Endpoint
                  </h3>
                </div>
                <div class="modal-body">
                  <ul class="blue-bullets mt-10">
                    <li>
                      Change in baseline MADRS total score at 24 hours after the
                      first dose was consistent with the primary analysis for
                      all prespecified subgroups.<sup>5</sup>
                    </li>
                  </ul>

                  <div class="text-center p-20 text-center">
                    <img src="assets/img/table-1.svg" alt="Chart" />
                  </div>
                  <p class="mt-20 mb-20 footer-text">
                    AD, antidepressant; CI, confidence interval; LSMD, least
                    squares mean difference; MADRS, Montgomery-Ǻsberg Depression
                    Rating Scale; PBO, placebo; SIBAT, Suicide Ideation and
                    Behavior Assessment Tool; SOC, standard of care.
                  </p>
                </div>
              </div>
            </div>
          </div>

          <div class="modal fade" id="ASPIREModal-4" role="dialog">
            <div class="modal-dialog">
              <!-- Modal content-->
              <div class="modal-content">
                <div class="modal-header">
                  <a
                    href="#"
                    class="close glyphicon glyphicon-remove"
                    data-dismiss="modal"
                  ></a>
                  <h3 class="modal-title">
                    Pooled Analysis of Secondary Suicidality Endpoints
                  </h3>
                </div>
                <div class="modal-body">
                  <ul class="blue-bullets mt-10">
                    <li>
                      SPRAVATO+SOC treatment was directionally favored for all
                      other indices of suicidality<sup>a</sup> (using the item
                      response theory model) at 4 hours and 24 hours after first
                      dose and on day 25.<sup>3-5</sup>
                    </li>
                  </ul>
                  <div class="text-center p-20 text-center">
                    <img src="assets/img/table-2.svg" alt="Chart" />
                  </div>
                  <p class="mt-20 mb-20 footer-text">
                    <sup>a</sup>Includes CGI-SS-r, the MADRS suicidal thoughts
                    item, CGI-SR-I, and clinician-rated and patient-reported
                    FoST.
                  </p>
                  <p class="footer-text">
                    CGI-SR-I, Clinical Global Impression - Imminent Suicide
                    Risk; CGI-SS-r, Clinical Global Impression - Severity of
                    Suicidality - revised; CI, confidence interval; FoST,
                    Frequency of Suicidal Thinking; LSMD, least squares mean
                    difference; MADRS, Montgomery-Ǻsberg Depression Rating
                    Scale; PBO, placebo; SOC, standard of care.
                  </p>
                </div>
              </div>
            </div>
          </div>

          <div class="modal fade" id="ASPIREModal-3" role="dialog">
            <div class="modal-dialog">
              <!-- Modal content-->
              <div class="modal-content">
                <div class="modal-header">
                  <a
                    href="#"
                    class="close glyphicon glyphicon-remove"
                    data-dismiss="modal"
                  ></a>
                  <h3 class="modal-title">Pooled Analysis of Remission</h3>
                </div>
                <div class="modal-body">
                  <ul class="blue-bullets mt-10">
                    <li>
                      More patients achieved remission (MADRS total score of
                      ≤12) in the SPRAVATO+SOC vs PBO+SOC at all timepoints
                      during the double-blind phase.<sup>5</sup>
                    </li>
                  </ul>
                  <div class="text-center p-20 text-center">
                    <img
                      src="assets/img/bar-chart-2.svg"
                      alt="Chart"
                      width="500px"
                    />
                  </div>
                  <p class="mt-20 mb-20 footer-text">
                    MADRS, Montgomery-Åsberg Depression Rating Scale; PBO,
                    placebo; SE, standard error; SOC, standard of care.
                  </p>
                </div>
              </div>
            </div>
          </div>

          <div class="modal fade" id="ASPIREModal-5" role="dialog">
            <div class="modal-dialog">
              <!-- Modal content-->
              <div class="modal-content">
                <div class="modal-header">
                  <a
                    href="#"
                    class="close glyphicon glyphicon-remove"
                    data-dismiss="modal"
                  ></a>
                  <h3 class="modal-title pr-20">
                    MADRS Total Score in the Double-Blind and Follow-up Phases
                    in ASPIRE-I
                  </h3>
                </div>
                <div class="modal-body">
                  <ul class="blue-bullets mt-10">
                    <li>
                      MADRS total scores were similar between treatment groups
                      through the follow-up phase (MMRM; observed cases).<sup
                        >3</sup
                      >
                    </li>
                  </ul>

                  <div class="text-center p-20 text-center">
                    <h1 class="heading1 text-center black-color mt-20 mb-20">
                      ASPIRE-I<sup>3</sup>
                    </h1>
                    <img src="assets/img/line-chart-4.svg" alt="Chart" />
                  </div>
                  <p class="mt-20 mb-20 footer-text">
                    Fu DJ, Ionescu DF, Li X, et al. Esketamine nasal spray for
                    rapid reduction of major depressive disorder symptoms in
                    patients who have active suicidal ideation with intent:
                    double-blind randomized study (ASPIRE I).<i>
                      J Clin Psychiatry.</i
                    >
                    2020;81(3):19m13191. Copyright 2020. Physicians Postgraduate
                    Press. Adapted by permission.
                  </p>
                  <p class="mt-20 mb-20 footer-text">
                    LS, least squares; MADRS, Montgomery-Ǻsberg Depression
                    Rating Scale; MMRM, mixed-effects model using repeated
                    measures; PBO, placebo; SE, standard error; SOC, standard of
                    care.
                  </p>
                </div>
              </div>
            </div>
          </div>

          <!-- priyanka modal end -->

          <div class="modal fade in" id="myModal5" role="dialog">
            <div class="modal-dialog">
              <!-- Modal content-->
              <div class="modal-content">
                <div class="modal-header">
                  <a
                    href="#"
                    class="close glyphicon glyphicon-remove"
                    data-dismiss="modal"
                  ></a>
                </div>
                <div class="modal-body">
                  <div class="overflow-x-auto">
                    <img
                      src="assets/img/figure_02.svg"
                      style="min-width: 600px"
                      alt="image"
                    />
                  </div>
                </div>
              </div>
            </div>
          </div>

          <!-- Modal 3 -->
          <div class="modal fade" id="myModal3" role="dialog">
            <div class="modal-dialog">
              <!-- Modal content-->
              <div class="modal-content">
                <div class="modal-header">
                  <a
                    href="#"
                    class="close glyphicon glyphicon-remove"
                    data-dismiss="modal"
                  ></a>
                  <h3 class="modal-title pr-20">
                    Most Common (≥10% in Either Group) TEAEs During the
                    Double-Blind Phase
                  </h3>
                </div>
                <div class="modal-body">
                  <div class="scroll-y-modal">
                    <img
                      src="assets/img/scroll-band-1.gif"
                      alt="Scroll"
                      width="100%"
                    />
                  </div>
                  <div class="overflow-x-auto">
                    <table
                      class="table table-striped table-bordered table-responsive"
                    >
                      <thead>
                        <tr>
                          <th colspan="4" class="text-center black-color bold">
                            ASPIRE-I<sup>3</sup>
                          </th>
                        </tr>
                        <tr>
                          <th
                            style="vertical-align: middle"
                            class="black-color bold"
                          >
                            TEAEs, n (%)
                          </th>
                          <th
                            class="text-center back-blue border-right-white1 bold"
                          >
                            SPRAVATO<br />+SOC<br />(n=113)
                          </th>
                          <th
                            class="text-center back-grey bold vertical-bottom"
                          >
                            PBO+SOC<br />
                            (n=112)
                          </th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td>Dizziness</td>
                          <td class="text-center">40 (35.4)</td>
                          <td class="text-center">10 (8.9)</td>
                        </tr>
                        <tr>
                          <td>Dissociation</td>
                          <td class="text-center">33 (29.2)</td>
                          <td class="text-center">4 (3.6)</td>
                        </tr>
                        <tr>
                          <td>Nausea</td>
                          <td class="text-center">23 (20.4)</td>
                          <td class="text-center">15 (13.4)</td>
                        </tr>
                        <tr>
                          <td>Headache</td>
                          <td class="text-center">21 (18.6)</td>
                          <td class="text-center">20 (17.9)</td>
                        </tr>
                        <tr>
                          <td>Somnolence</td>
                          <td class="text-center">21 (18.6)</td>
                          <td class="text-center">11 (9.8)</td>
                        </tr>
                        <tr>
                          <td>Blood pressure increased</td>
                          <td class="text-center">19 (16.8)</td>
                          <td class="text-center">6 (5.4)</td>
                        </tr>
                        <tr>
                          <td>Dysgeusia</td>
                          <td class="text-center">16 (14.2)</td>
                          <td class="text-center">11 (9.8)</td>
                        </tr>
                        <tr>
                          <td>Constipation</td>
                          <td class="text-center">15 (13.3)</td>
                          <td class="text-center">5 (4.5)</td>
                        </tr>
                      </tbody>
                    </table>
                  </div>
                  <div class="overflow-x-auto">
                    <table
                      class="table table-striped table-bordered table-responsive"
                    >
                      <thead>
                        <tr>
                          <th colspan="4" class="text-center black-color bold">
                            ASPIRE-II<sup>4</sup>
                          </th>
                        </tr>
                        <tr>
                          <th
                            style="vertical-align: middle"
                            class="black-color bold"
                          >
                            TEAEs, n (%)
                          </th>
                          <th
                            class="text-center back-blue border-right-white1 bold"
                          >
                            SPRAVATO<br />+SOC<br />(n=114)
                          </th>
                          <th
                            class="text-center back-grey bold vertical-bottom"
                          >
                            PBO+SOC<br />(n=113)
                          </th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td>Dizziness</td>
                          <td class="text-center">47 (41.2)</td>
                          <td class="text-center">21 (18.6)</td>
                        </tr>
                        <tr>
                          <td>Dissociation</td>
                          <td class="text-center">44 (38.6)</td>
                          <td class="text-center">9 (8.0)</td>
                        </tr>
                        <tr>
                          <td>Nausea</td>
                          <td class="text-center">38 (33.3)</td>
                          <td class="text-center">16 (14.2)</td>
                        </tr>
                        <tr>
                          <td>Dysgeusia</td>
                          <td class="text-center">29 (25.4)</td>
                          <td class="text-center">18 (15.9)</td>
                        </tr>
                        <tr>
                          <td>Somnolence</td>
                          <td class="text-center">26 (22.8)</td>
                          <td class="text-center">12 (10.6)</td>
                        </tr>
                        <tr>
                          <td>Headache</td>
                          <td class="text-center">25 (21.9)</td>
                          <td class="text-center">26 (23.0)</td>
                        </tr>
                        <tr>
                          <td>Paresthesia</td>
                          <td class="text-center">23 (20.2)</td>
                          <td class="text-center">7 (6.2)</td>
                        </tr>

                        <tr>
                          <td>Vomiting</td>
                          <td class="text-center">18 (15.8)</td>
                          <td class="text-center">5 (4.4)</td>
                        </tr>
                        <tr>
                          <td>Anxiety</td>
                          <td class="text-center">17 (14.9)</td>
                          <td class="text-center">7 (6.2)</td>
                        </tr>
                        <tr>
                          <td>Vision blurred</td>
                          <td class="text-center">17 (14.9)</td>
                          <td class="text-center">6 (5.3)</td>
                        </tr>
                        <tr>
                          <td>Sedation</td>
                          <td class="text-center">16 (14.0)</td>
                          <td class="text-center">3 (2.7)</td>
                        </tr>
                        <tr>
                          <td>Paresthesia oral</td>
                          <td class="text-center">14 (12.3)</td>
                          <td class="text-center">3 (2.7)</td>
                        </tr>

                        <tr>
                          <td>Euphoric mood</td>
                          <td class="text-center">13 (11.4)</td>
                          <td class="text-center">1 (0.9)</td>
                        </tr>
                        <tr>
                          <td>Hypoesthesia</td>
                          <td class="text-center">12 (10.5)</td>
                          <td class="text-center">1 (0.9)</td>
                        </tr>
                      </tbody>
                    </table>
                  </div>
                  <p class="footer-text">
                    PBO, placebo; SOC, standard of care; TEAE,
                    treatment-emergent adverse event.
                  </p>
                </div>
              </div>
            </div>
          </div>

          <div class="modal fade" id="myModal6" role="dialog">
            <div class="modal-dialog">
              <!-- Modal content-->
              <div class="modal-content">
                <div class="modal-header">
                  <a
                    href="#"
                    class="close glyphicon glyphicon-remove"
                    data-dismiss="modal"
                  ></a>
                  <h3 class="modal-title">
                    TEAEs and SAEs During the Follow-up Phase: ASPIRE-I<sup
                      >3</sup
                    >
                  </h3>
                </div>
                <div class="modal-body">
                  <div class="scroll-y-modal">
                    <img
                      src="assets/img/scroll-band-1.gif"
                      alt="Scroll"
                      width="100%"
                    />
                  </div>
                  <div class="overflow-x-auto">
                    <table
                      class="table table-striped table-bordered table-responsive"
                    >
                      <thead>
                        <tr>
                          <th class="black-color bold">
                            Adverse events, n (%)
                          </th>
                          <th
                            class="text-center back-blue border-right-white1 bold"
                          >
                            SPRAVATO<br />+SOC<sup>a</sup><br />(n=101)
                          </th>
                          <th
                            class="text-center back-grey bold vertical-bottom"
                          >
                            PBO+SOC<sup>a</sup><br />
                            (n=91)
                          </th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td colspan="3" class="black-color bold">
                            TEAEs ≥5% in either treatment group
                          </td>
                        </tr>
                        <tr>
                          <td>Depression</td>
                          <td class="text-center">11 (10.9)</td>
                          <td class="text-center">3 (3.3)</td>
                        </tr>
                        <tr>
                          <td>Headache</td>
                          <td class="text-center">6 (5.9)</td>
                          <td class="text-center">7 (7.7)</td>
                        </tr>
                        <tr>
                          <td>Depression suicidal</td>
                          <td class="text-center">5 (5.0)</td>
                          <td class="text-center">3 (3.3)</td>
                        </tr>
                        <tr>
                          <td>Suicidal ideation</td>
                          <td class="text-center">5 (5.0)</td>
                          <td class="text-center">5 (5.5)</td>
                        </tr>
                        <tr>
                          <td>Anxiety</td>
                          <td class="text-center">3 (3.0)</td>
                          <td class="text-center">9 (9.9)</td>
                        </tr>
                        <tr>
                          <td colspan="3" class="black-color bold">SAEs</td>
                        </tr>
                        <tr>
                          <td>Depression suicidal</td>
                          <td class="text-center">5 (5.0)</td>
                          <td class="text-center">3 (3.3)</td>
                        </tr>

                        <tr>
                          <td>Suicide attempt</td>
                          <td class="text-center">3 (3.0)</td>
                          <td class="text-center">2 (2.2)</td>
                        </tr>

                        <tr>
                          <td>Depression</td>
                          <td class="text-center">2 (2.0)</td>
                          <td class="text-center">1 (1.1)</td>
                        </tr>
                        <tr>
                          <td>Suicidal ideation</td>
                          <td class="text-center">2 (2.0)</td>
                          <td class="text-center">3 (3.3)</td>
                        </tr>
                        <tr>
                          <td>Completed suicide</td>
                          <td class="text-center">1 (1.0)</td>
                          <td class="text-center">0</td>
                        </tr>
                        <tr>
                          <td>Major depression</td>
                          <td class="text-center">1 (1.0)</td>
                          <td class="text-center">0</td>
                        </tr>
                        <tr>
                          <td>Rhabdomyolysis</td>
                          <td class="text-center">0</td>
                          <td class="text-center">1 (1.1)</td>
                        </tr>
                      </tbody>
                    </table>
                  </div>
                  <p class="footer-text">
                    <sup>a</sup>Treatment as assigned during the double-blind
                    phase. During the follow-up phase, patients were only
                    treated by SOC antidepressant therapy.
                  </p>

                  <p class="footer-text">
                    PBO, placebo; SOC, standard of care; TEAE,
                    treatment-emergent adverse event.
                  </p>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </main>
  </body>
</html>
